Breakthrough! Chinese-Made Sterile ART Reagents Receive FDA Clearance, Ending Monopoly by European, American, and Japanese Firms

VCBeat (WeChat: vcbeat) has learned that after three years of effort, the innovative company VitaVitro (Shenzhen Weituo Biotechnology Co., Ltd.) announced today that it has recently obtained FDA clearance—specifically, 510(k) Premarket Notification—for its human embryo and oocyte cryopreservation/thawing kit, breaking the monopoly held by European and American products in the upstream segment of assisted reproductive technology.

Data indicates that the market for high-end reagents used in assisted reproductive technology (ART) laboratories has long been monopolized by companies from Europe, the United States, and Japan, represented by Sweden’s Vitrolife, Japan’s Kato Ladies Clinic, and the US-based Origio. According to the latest “Survey Report on the Current Status of Infertility in China,” jointly released by the China Population Association and the National Health and Family Planning Commission, approximately 1.23 million cycles of ART treatment were completed nationwide in 2017. Despite the large and rapidly growing market, there are few domestically produced sterile reagent products for assisted reproduction that have obtained medical device registration certificates for market access.

In 2014, the founding team of VitaVitro established an R&D team in China, completing the entire process from product development and scaled-up production to process stabilization within two years.

VCBeat has learned that the company has taken the lead in obtaining FDA clearance and partial CE certification for its embryo cryopreservation/thawing kit, while multiple products have been approved to enter multi-center clinical trials in China. In the future, the company will continue to translate internationally leading laboratory technologies into commercial products, expanding its product line to include a full range of sterile reagents and high-end consumables for assisted reproductive technology (ART), as well as active specialized ART equipment—particularly its upcoming launch of the world’s first automated embryo/oocyte processing system. The company is committed to providing comprehensive solutions to ART laboratories worldwide.

According to available information, the company has participated in the American Society for Reproductive Medicine (ASRM) Annual Meeting (2017) and the European Society of Human Reproduction and Embryology (ESHRE) Annual Meeting (2018), garnering extensive attention from peers. Notably, certain sterile reagent products offered by the company are comparable in quality to those of international counterparts and offer advantages in ease of use. The company’s independently developed automated embryo/oocyte handling equipment is poised to drive transformation in assisted reproductive technology (ART) laboratory operations, significantly reducing the high-difficulty, labor-intensive, and error-prone workload for laboratory personnel, while standardizing and digitizing laboratory workflows.

Ms. Lin Xiaozhen, Co-founder and Chairwoman of the Company, stated, “Obtaining FDA certification marks a significant milestone in the three years since our establishment. Over the past three years, our technological development and marketing efforts have been primarily focused on overseas markets. In China, the market for high-value assisted reproductive technology (ART) devices is dominated by imported products. It is our important responsibility to deliver higher-quality products, develop more advanced technologies, and create greater benefits for healthcare professionals and patients, particularly as a domestic brand that has pioneered entry into the international market. Meanwhile, we also hope to see an increasing number of Chinese manufacturers join us in jointly establishing industry and national standards for ART devices in China.”